Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 17
Clinical Characteristics and Major Adverse Cardiovascular Events in Diabetic and Non-Diabetic Patients with Vasospastic Angina [Response to Letter]
Authors Teragawa H , Uchimura Y, Oshita C, Hashimoto Y, Nomura S
Received 18 July 2024
Accepted for publication 30 July 2024
Published 1 August 2024 Volume 2024:17 Pages 2911—2912
Hiroki Teragawa, Yuko Uchimura, Chikage Oshita, Yu Hashimoto, Shuichi Nomura
Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan
Correspondence: Hiroki Teragawa, Department of Cardiovascular Medicine, JR Hiroshima Hospital, 3-1-36 Futabanosato, Higashi-ku, Hiroshima, 732-0057, Japan, Tel +81 82 262 1171, Fax +81 82 262 1499, Email [email protected]
View the original paper by Dr Teragawa and colleagues
This is in response to the Letter to the Editor
Dear editor
We have received a letter from Dr. Zhang et al1 inquiring about the significance of diabetes mellitus (DM) on the prognosis of patients with vasospastic angina (VSA) in our recently published paper.2 Here, we answer their questions to the best of our knowledge. First, we thank you for your interest in reading our paper.
The key point of our paper2 is that patients with VSA with DM exhibited significantly more atherosclerotic lesions, and experienced fewer focal spasms. However, patients with focal spasms may demonstrate a worse prognosis if they also have DM. Hence, we may need to observe such patients more carefully. Although the mechanism is entirely hypothetical, we have considered the possibility that focal spasm is frequently associated with atherosclerotic lesions;3 in addition, DM may have some effect on the instability of these lesions. However, as you have emphasized, the association of DM with focal spasm, which tends to be less frequent, is not beyond the scope of our study.
As mentioned in the study limitations, the small number of focal spasms in patients with VSA with DM may have affected our analyses. In this study, patients with multi-vessel spasms, including both focal and diffuse spasms were categorized as focal spasms. Further, the major adverse cardiovascular events include readmission for cardiovascular diseases. Thus, the definitions of focal spasms and major adverse cardiac events (MACE) may vary from those in previous studies.4,5 Finally, the present study rarely introduced sodium-glucose transporter 2 inhibitors and glucagon-like peptide-1 agonists, which have recently become mainstream in DM treatment.6 Our study was meaningful because it reminded us that DM treatment should strongly emphasize managing VSA. However, the association between DM and VSA and focal spasm needs to be clarified in the future, including recent treatments in a multicenter registry, etc., by matching the definitions of focal spasm and MACE.
Again, we sincerely appreciate your interest in reading our manuscript.
Disclosure
The authors report no conflicts of interest in this communication.
References
1. Zhang B, Wang J. Clinical characteristics and major adverse cardiovascular events in diabetic and non-diabetic patients with vasospastic angina [Letter]. Diabetes Metabol Syndr Obes. 2024;17:2735–2736. doi:10.2147/dmso.S486527
2. Teragawa H, Uchimura Y, Oshita C, et al. Clinical characteristics and major adverse cardiovascular events in diabetic and non-diabetic patients with vasospastic angina. Diabetes Metab Syndr Obes. 2024;17:2135–2146. doi:10.2147/DMSO.S462234
3. Kitano D, Takayama T, Sudo M, et al. Angioscopic differences of coronary intima between diffuse and focal coronary vasospasm: comparison of optical coherence tomography findings. J Cardiol. 2018;72(3):200–207. doi:10.1016/j.jjcc.2018.04.013
4. Sato K, Kaikita K, Nakayama N, et al. Coronary vasomotor response to intracoronary acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive patients with coronary spasm: analysis of a single-center study over 20 years. J Am Heart Assoc. 2013;2(4):e000227. doi:10.1161/JAHA.113.000227
5. Nishimiya K, Suda A, Fukui K, et al. Prognostic links between OCT-delineated coronary morphologies and coronary functional abnormalities in patients with INOCA. JACC Cardiovasc Interv. 2021;14(6):606–618. doi:10.1016/j.jcin.2020.12.025
6. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.